Top Page
Haleon PLC
(LSE:HLN)
Haleon PLC (HLN) vs. iShares MSCI United Kingdom ETF (EWC)
Haleon PLC Business Overview & Revenue Model
Haleon PLC Earnings Call Summary
Haleon PLC Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.02B | 11.23B | 11.30B | 10.86B | 9.54B | 9.89B |
| Gross Profit | 6.81B | 6.82B | 6.75B | 6.73B | 5.95B | 5.91B |
| EBITDA | 2.79B | 2.68B | 2.67B | 2.68B | 2.21B | 2.19B |
| Net Income | 1.52B | 1.44B | 1.05B | 1.06B | 1.39B | 1.15B |
Balance Sheet | ||||||
| Total Assets | 31.83B | 34.31B | 34.05B | 34.81B | 34.45B | 34.13B |
| Cash, Cash Equivalents and Short-Term Investments | 676.00M | 2.19B | 1.04B | 684.00M | 414.00M | 334.00M |
| Total Debt | 8.54B | 10.10B | 9.46B | 10.44B | 991.00M | 487.00M |
| Total Liabilities | 15.83B | 18.09B | 17.33B | 18.36B | 7.97B | 7.91B |
| Stockholders Equity | 15.94B | 16.17B | 16.61B | 16.33B | 26.36B | 26.11B |
Cash Flow | ||||||
| Free Cash Flow | 931.00M | 1.98B | 1.76B | 1.74B | 1.06B | 1.09B |
| Operating Cash Flow | 1.03B | 2.30B | 2.10B | 2.06B | 1.36B | 1.41B |
| Investing Cash Flow | -76.00M | 528.00M | -134.00M | -8.78B | -33.00M | 1.03B |
| Financing Cash Flow | -2.52B | -1.54B | -1.57B | 6.91B | -1.24B | -2.44B |
Haleon PLC Technical Analysis
Haleon PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £3.32B | 11.63 | 15.66% | 4.20% | 3.73% | 27.13% | |
73 Outperform | £32.36B | 21.62 | 9.35% | 1.52% | -2.12% | 42.10% | |
67 Neutral | £164.33M | -6.71 | 2.83% | 2.18% | 8.74% | -166.50% | |
56 Neutral | £693.98M | -13.69 | ― | ― | -0.28% | 22.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Haleon PLC Corporate Events
Haleon PLC announced that as of November 30, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 45,882,158 held as treasury shares. This results in 8,906,471,490 shares with voting rights, a figure crucial for shareholders and stakeholders for notification obligations under the FCA’s rules. This announcement is significant for stakeholders as it provides clarity on voting rights and helps in regulatory compliance.
Haleon PLC announced the notification of share transactions by key managerial personnel, Adrian Morris and Tamara Rogers, involving the acquisition of Partnership Shares and the award of Matching Shares under the company’s Share Reward Plan. This disclosure, in line with UK Market Abuse Regulation, underscores Haleon’s commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and market perception.
Haleon PLC has announced the resignation of Sir Dave Lewis as Chair and the appointment of Vindi Banga as his successor, effective January 1, 2026. Vindi Banga, who has been a Senior Independent Director since Haleon’s listing in 2022, brings extensive global corporate and commercial leadership experience, having previously held significant roles at Unilever and other major companies. This leadership transition is expected to support Haleon’s continued development and strengthen its position in the competitive consumer health industry.
Haleon PLC announced that as of October 31, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 45,930,962 held as treasury shares. This results in 8,906,422,686 ordinary shares with voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This update is significant for stakeholders as it impacts the calculation of notifiable interests in the company.
Haleon PLC announced the release of its Q3 trading statement for 2025, highlighting its financial performance and strategic initiatives. The statement is accessible on the company’s website and through the Financial Conduct Authority’s National Storage Mechanism. A presentation for analysts and shareholders, led by CFO Dawn Allen, will provide further insights into the company’s operations and future outlook, potentially impacting its market positioning and stakeholder interests.
Haleon PLC has announced the notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) under the UK Market Abuse Regulation. The transactions involve the acquisition of Partnership Shares and the award of Matching Shares under the company’s Share Reward Plan by Adrian Morris, General Counsel, and Tamara Rogers, Chief Marketing Officer. This move reflects the company’s ongoing commitment to aligning managerial interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
Haleon PLC announced the appointment of Tracy Clarke, a Non-Executive Director, to the board of Inchcape PLC, effective December 31, 2025. This strategic move may enhance Haleon’s industry positioning by fostering stronger leadership connections and potentially influencing future collaborations or market strategies.
Haleon PLC has completed the final tranche of its share buyback programme, purchasing 1,561,229 ordinary shares to be held as treasury shares. This move finalizes a series of buybacks initiated earlier in the year, which included shares repurchased from Pfizer, totaling 175,806,525 shares. The completion of this programme is a strategic step for Haleon, impacting its capital structure and potentially enhancing shareholder value.
Haleon PLC announced that as of September 30, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 44,400,783 held as treasury shares. This results in 8,907,952,865 shares with voting rights, which shareholders and others with notification obligations should use as the denominator for calculating their interest in the company. This update is crucial for stakeholders to comply with the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the purchase of 1,500,000 ordinary shares as part of its share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and could influence shareholder decisions regarding their interests in the company.
Haleon PLC announced the purchase of 1,996,340 ordinary shares as part of its ongoing share buyback program. This transaction, completed on September 29, 2025, is part of the second tranche of the program announced earlier in July. The purchased shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is likely aimed at consolidating shareholder value and optimizing capital structure, reflecting positively on Haleon’s market positioning.
Haleon PLC announced the purchase of 1,996,340 ordinary shares as part of the second tranche of its share buyback program. The purchased shares will be held as treasury shares, impacting the company’s total share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
Haleon PLC announced the acquisition of ordinary shares by key managerial personnel through dividend reinvestment. This transaction, involving figures such as the CEO and regional presidents, underscores the company’s commitment to aligning management interests with shareholder value, potentially impacting its market perception positively.
Haleon PLC announced the purchase of 2,318,700 ordinary shares as part of its ongoing share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
Haleon PLC announced the purchase of 3,251,858 ordinary shares as part of its ongoing share buyback program. This move is part of the second tranche of the program, initially announced in July 2025. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This strategic financial maneuver is likely aimed at enhancing shareholder value and optimizing capital structure, reflecting Haleon’s commitment to maintaining a robust financial position.
Haleon PLC has announced the purchase of 5,150,000 ordinary shares as part of the second tranche of its share buyback program. This move is intended to strengthen the company’s financial position by holding the purchased shares as treasury shares, impacting the number of shares with voting rights and potentially influencing shareholder decisions.
Haleon PLC announced the purchase of 5,150,000 ordinary shares as part of its share buyback program, which commenced on July 31, 2025. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
Haleon PLC announced the notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) in compliance with the UK Market Abuse Regulation. The transactions involved the acquisition of ordinary shares through dividend reinvestment by Tamara Rogers, Chief Marketing Officer, and Alan Stewart, Independent Non-Executive Director, on the London Stock Exchange. This announcement highlights the company’s adherence to regulatory requirements and transparency in its operations, potentially impacting stakeholder trust and market perception.
Haleon PLC announced the purchase of 4,150,000 ordinary shares as part of the second tranche of its share buyback program. The company plans to hold these shares as treasury shares, impacting its registered share capital and the number of shares with voting rights. This move is part of Haleon’s strategic financial management, potentially affecting shareholder interests and market positioning.
Haleon PLC announced the purchase of 4,314,000 ordinary shares as part of the second tranche of its share buyback program. This strategic move aims to consolidate the company’s share capital and potentially enhance shareholder value by holding the purchased shares as treasury shares. Following this transaction, Haleon’s registered share capital comprises 8,952,353,648 ordinary shares, with 18,887,545 held as treasury shares, affecting the number of shares with voting rights and shareholder notifications under regulatory rules.
Haleon PLC has announced the purchase of 5,214,540 ordinary shares as part of the second tranche of its share buyback program. This move is aimed at consolidating its capital structure by holding the purchased shares as treasury shares, impacting the company’s share capital and voting rights. The transaction reflects Haleon’s strategic financial management and could influence shareholder decisions under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the purchase of 5,357,044 ordinary shares as part of the second tranche of its share buyback program. The company plans to hold these shares as treasury shares, impacting its registered share capital and the number of shares with voting rights. This move reflects Haleon’s strategic financial management and may influence shareholder decisions regarding their interests in the company.
Haleon PLC announced the purchase of 1,500,000 ordinary shares as part of the second tranche of its share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move reflects Haleon’s strategic financial management and may influence shareholder decisions under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the purchase of 997,991 ordinary shares as part of the second tranche of its share buyback program. This move is likely to impact the company’s share capital, with 23,788 shares being canceled and 974,203 held as treasury shares, potentially influencing shareholder voting rights and market perception.